Select region

NIV NAVA in pediatric acute respiratory failure

Watch our webinar featuring Prof. Daniele De Luca now! During this 60 minute event, Prof. De Luca discussed the results of a controlled before-after quality improvement study, published in 2021 in the “Anesthesia, Analgesia and Critical Care” journal. 
 
This study shows that NIV-NAVA, delivered as first-line noninvasive respiratory support (NRS) in pediatric moderate AHRF of infectious origin, is associated with a lower intubation rate, shorter PICU and hospital length of stay, as well as early improvement of physiological parameters compared to NIV-PS traditional treatment including endotracheal intubation and mechanical ventilation.

You are now leaving Getinge.com. You might access content  not managed by Getinge team, in that case Getinge can not be hold responsible of the content. 

I understand!

Dear user, you have clicked a link and will now see International fallback content.
Getinge ANZ does not review or control this content. It is possible that some of the products on Getinge International are not approved in your country. For more specific Australian information please contact us 

OK!

Dear user, You now see International fallback content. Getinge ANZ does not review or control this content. It is possible that some of the products on Getinge international are not approved in your country. For more specific  information relevant for your region please contact us.